MDT Stock Recent News
MDT LATEST HEADLINES
Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic's NYSE: MDT share price is down significantly from its peak in 2021, providing investors a deep-value opportunity. The stock price is down because of the post-COVID correction and headwinds leading to sluggish growth, which are factors that will not last forever.
New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland , Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM).
Medtronic plc reported Q2 earnings today, with revenues of $8.4bn, up 5% year-on-year, adjusted EPS of $1.26, supported by a dividend yielding 3.2%. Despite consistent mid-single-digit revenue growth and new product launches, Medtronic's share price remains flat due to unpredictable net income and modest innovation. CEO Geoff Martha highlighted strong performance and innovation in key fields such as diabetes and hypertension, but stopped short of providing specific long-term growth guidance, keeping market sentiment lukewarm.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
Medtronic plc (NYSE:MDT ) Q2 2025 Earnings Conference Call November 19, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim CFO Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Brett Wall - EVP and President, Neuroscience Conference Call Participants Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Pito Chickering - Deutsche Bank Anthony Petrone - Mizuho Securities Rich Newitter - Truist Securities Danielle Antalffy - UBS Joanne Wuensch - Citi Matt Miksic - Barclays Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations and I appre
MDT delivers diversified growth across all its segments in the second quarter of fiscal 2025.
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended October 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.